Help Privacy Policy Disclaimer
  Advanced SearchBrowse


  Relationship of serum beta-synuclein with blood biomarkers and brain atrophy

Oeckl, P., Anderl-Straub, S., Danek, A., Diehl-Schmid, J., Fassbender, K., Fliessbach, K., et al. (2022). Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimer's and Dementia. doi:10.1002/alz.12790.

Item is


show Files
hide Files
Oeckl_2022.pdf (Publisher version), 6MB
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
Copyright Info:




Oeckl, Patrick1, 2, Author
Anderl-Straub, Sarah1, Author
Danek, Adrian3, Author
Diehl-Schmid, Janine4, Author
Fassbender, Klaus5, Author
Fliessbach, Klaus6, Author
Halbgebauer, Steffen1, Author
Huppertz, Hans-Jürgen7, Author
Jahn, Holger8, Author
Kassubek, Jan1, 2, Author
Kornhuber, Johannes9, Author
Landwehrmeyer, Bernhard1, Author
Lauer, Martin10, Author
Prudlo, Johannes11, Author
Schneider, Anja6, Author
Schroeter, Matthias L.12, 13, Author           
Steinacker, Petra1, Author
Volk, Alexander E.14, Author
Wagner, Matias15, Author
Winkelmann, Juliane15, Author
Wiltfang, Jens16, AuthorLudolph, Albert C.1, 2, AuthorOtto, Markus1, 17, Author more..
1Department of Neurology, Ulm University, Germany, ou_persistent22              
2German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany, ou_persistent22              
3Department of Neurology, Ludwig Maximilians University Munich, Germany, ou_persistent22              
4Department of Psychiatry and Psychotherapy, TU Munich, Germany, ou_persistent22              
5Department of Neurology, Saarland University Homburg, Germany, ou_persistent22              
6Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Germany, ou_persistent22              
7Swiss Epilepsy Centre, Zurich, Switzerland, ou_persistent22              
8Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany, ou_persistent22              
9Department of Psychiatry, Friedrich Alexander University Erlangen, Germany, ou_persistent22              
10Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Germany, ou_persistent22              
11Department of Neurology, University Medicine Rostock, Germany, ou_persistent22              
12Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634549              
13Clinic for Cognitive Neurology, University of Leipzig, Germany, ou_persistent22              
14Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Germany, ou_persistent22              
15Institut für Neurogenomik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany, ou_persistent22              
16Department of Psychiatry and Psychotherapy, Georg August University, Germany, ou_persistent22              
17Department of Neurology, Martin Luther University Halle-Wittenberg, Germany, ou_persistent22              


Free keywords: Alzheimer's disease; FTLD; NfL; Beta-synuclein; Blood biomarker; Brain atrophy; Dementia; Frontotemporal lobar degeneration; p-tau181; Synaptic degeneration.
 Abstract: Background: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).

Methods: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.

Results: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.

Discussion: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.

Highlights: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).


Language(s): eng - English
 Dates: 2022-07-212022-05-262022-08-092022-09-21
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1002/alz.12790
Other: online ahead of print
PMID: 36129098
 Degree: -



Legal Case


Project information

show hide
Project name : -
Grant ID : 01GI1007A
Funding program : -
Funding organization : German Federal Ministry of Education and Research
Project name : -
Grant ID : EXC2145SyNergy–ID390857198
Funding program : -
Funding organization : Deutsche Forschungsgemeinschaft (DFG)

Source 1

Title: Alzheimer's and Dementia
Source Genre: Journal
Publ. Info: New York, NY, USA : Elsevier
Pages: - Volume / Issue: - Sequence Number: - Start / End Page: - Identifier: ISSN: 1552-5260
CoNE: https://pure.mpg.de/cone/journals/resource/1552-5260